OCTREOSCAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Octreoscan, and what generic alternatives are available?
Octreoscan is a drug marketed by Curium and is included in one NDA.
The generic ingredient in OCTREOSCAN is indium in-111 pentetreotide kit. There are twenty-four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indium in-111 pentetreotide kit profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Octreoscan
A generic version of OCTREOSCAN was approved as indium in-111 pentetreotide kit by SUN PHARM INDS INC on July 1st, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OCTREOSCAN?
- What are the global sales for OCTREOSCAN?
- What is Average Wholesale Price for OCTREOSCAN?
Summary for OCTREOSCAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 20 |
| Patent Applications: | 79 |
| What excipients (inactive ingredients) are in OCTREOSCAN? | OCTREOSCAN excipients list |
| DailyMed Link: | OCTREOSCAN at DailyMed |
Recent Clinical Trials for OCTREOSCAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AHS Cancer Control Alberta | Phase 1/Phase 2 |
| Alexander McEwan | Phase 1/Phase 2 |
| AC Camargo Cancer Center | Phase 2 |
US Patents and Regulatory Information for OCTREOSCAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Curium | OCTREOSCAN | indium in-111 pentetreotide kit | INJECTABLE;INJECTION | 020314-001 | Jun 2, 1994 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OCTREOSCAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Curium | OCTREOSCAN | indium in-111 pentetreotide kit | INJECTABLE;INJECTION | 020314-001 | Jun 2, 1994 | ⤷ Sign Up | ⤷ Sign Up |
| Curium | OCTREOSCAN | indium in-111 pentetreotide kit | INJECTABLE;INJECTION | 020314-001 | Jun 2, 1994 | ⤷ Sign Up | ⤷ Sign Up |
| Curium | OCTREOSCAN | indium in-111 pentetreotide kit | INJECTABLE;INJECTION | 020314-001 | Jun 2, 1994 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OCTREOSCAN
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
